Pharmacy Call to Action: FDA Drug Importation Proposal Jeopardizes Patient Safety
On December 23, 2019, the Food and Drug Administration (FDA) published a proposed rule that, if finalized, would create a program for the legal importation of certain drugs from Canada to the United States. FDA’s drug importation program is NOT a safe way to reduce drug prices, and it puts patients at risk.
We’ve submitted APhA’s comments, as well as collaborated on joint comments with our colleague pharmacy organizations ASHP, AMCP, NCPA, NASPA, ASCP, and CPNP. FDA’s drug importation proposal jeopardizes patient safety, undermines track and trace, creates pharmacy operation disruptions, and fails to produce significant cost savings to American consumers. Thank you to every pharmacist who shared their concerns with FDA!
Why This Matters
Pharmacists are the gatekeeper of safe medications between the supply chain and their patients. But the safeguards to protect Americans that are in place would be undermined if this proposal is finalized as written. This video explains how a drug importation program would work under this proposed rule and provides an overview of concerns with the rule as written.
Download The Backgrounder
For more information about how the proposed importation program would work, and how it impacts you and your patients, download our backgrounder. This document outlines the entities involved and provides an overview of where APhA and National Alliance of State Pharmacy Associations (NASPA) stand on the issues that would result if this proposed rule was finalized as written.